News

DNA hypomethylation makes humans prone to diseases
Enlarge image

SciencePoland

DNA hypomethylation makes humans prone to diseases

22.05.2012 - A Polish-US research team has found that hypomethylation destablises DNA and boosts the risk of neurological diseases.

Warsaw/Houston –Bioinformaticians from Warsaw University and the Baylor College of Medicine have provided an explanation for how disease-associated mutation hotspots may arise. According to results of the group under Aleksandar Milosavljevic and Tomasz Gambin, regions on human chromosomes that carry only few so-called methylation marks show a tenfold higher number of structural mutations than the genome-wide average. Patients diagnosed with schizophrenia, bipolar disorder, developmental delay, and autism had a significant higher amount of such predetermined breaking points, (PloS Genetics 8(5): e1002692).

The researchers suggest that the amount of methylation might mediate genomic stability.  They compared methylome maps from human sperm cell samples with publicly available structural variation data. Their results points to a strong association of germline hypomethylation and genomic instability which might lead to new diagnostic and therapeutic approaches. "We have found that these rare and de novo structural variants, as well as changes of the human genome that have accumulated the fastest since the branching chimpanzee, are significantly concentrated within methylation deserts," senior author Aleksandar Milosavljevic, a molecular and human genetics researcher at Baylor College of Medicine, said in a statement.

Lack of methylation of genomic DNA has been previously associated with high structural mutability in gibbons and in human cancer cells, but the association with structural mutability in the human germline has not been explored prior to this study.

http://www.european-biotechnology-news.com/news/news/2012-02/dna-hypomethylation-makes-humans-prone-to-diseases.html

AntibodiesDenmarkNetherlands

22.05.2015 Dutch arGEN-X and Danish LEO Pharma are pairing up to develop antibody-based treatments for the chronic inflammation that causes many skin conditions.

M&ANetherlandsGermanyEU

12.05.2015 US pharma is coming to European biotech to fill their pipeline. Pfizer is paying €77.5m for an option on Dutch AM-Pharma, while Juno Therapeutics acquired German biotech Stage Cell Therapeutics for around €72m.

Rare diseasesItalyGermanyPoland

15.05.2015 Rome-based pharmaceutical group Sigma-Tau has sold its blood cancer drug programme Oncaspar to US company Baxter, who aims to spin out its biopharma business.



BiologicsFinlandNetherlandsEU

26.05.2015 The Finnish Medicines Agency Fimea has joined the Dutch MEB in its stance on the interchangeability of biosimilars. The Fimea now sees physician-driven switching of biologics as unproblematic.

SurveyGermany

06.05.2015 More revenue, more staff, more funding: in the German biotech industry, all signs are pointing towards growth.

M&AUKSweden

18.05.2015 Double deal for allergy: UK’s speciality biopharma Circassia is boosting its asthma pipeline with the acquisition of Swedish asthma specialist Aerocrine as well as fellow British Prosonix.

FinancingUK

20.05.2015 The Scottish Government has announced it will double the amount of funds for rare diseases. The New Medicines Fund that was created last year for this purpose will be increased to £80m (€112m).

M&ASwitzerland

04.05.2015 Swiss crop chemical maker Syngenta AG is in talks with US company Monsanto to discuss a possible merger, insiders say.

BiofuelsEU

30.04.2015 The European Parliament has given the go-ahead on a new law limiting the use of harmful crop-based biofuel in the transport sector. The decision marks a breakthrough in the EU’s approach to biofuels.

Events

All Events

Partner-Events

Frankfurt am Main (DE)

ACHEMA 2015

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • BASILEA133.60 CHF4.70%
  • WILEX4.20 EUR3.45%
  • STRATEC BIOMEDICAL48.52 EUR3.23%

FLOP

  • MEDIGENE8.58 EUR-4.88%
  • PAION2.51 EUR-4.56%
  • CYTOS0.63 CHF-3.08%

TOP

  • 4SC4.65 EUR257.7%
  • SYNGENTA422.00 CHF27.6%
  • BASILEA133.60 CHF14.3%

FLOP

  • CYTOS0.63 CHF-41.7%
  • MEDIGENE8.58 EUR-30.9%
  • CO.DON2.89 EUR-13.7%

TOP

  • WILEX4.20 EUR431.6%
  • FORMYCON27.70 EUR303.8%
  • 4SC4.65 EUR297.4%

FLOP

  • MOLOGEN4.92 EUR-54.4%
  • BIOFRONTERA2.30 EUR-25.8%
  • CO.DON2.89 EUR-21.5%

No liability assumed, Date: 26.05.2015